Sandoz Group (SDZ.SW)

Executive Summary

Sandoz Group (SDZ.SW) is a global leader in generics and biosimilars, having been spun off from Novartis in 2023. With a pipeline of 129 drug candidates and a portfolio spanning generics and biosimilars in immunology, oncology, and other therapeutic areas, the company is positioned to capitalize on the wave of biologic patent expirations. Its commercial footprint covers over 100 markets, and its strategic focus on cost-effective off-patent medicines addresses growing healthcare system pressures. The company's independence allows it to pursue aggressive growth in the biosimilar space, where it competes with major players like Pfizer and Amgen. Key near-term catalysts include regulatory decisions and launches of high-value biosimilars, which could drive significant revenue growth and margin expansion.

Upcoming Catalysts (preview)

• Q3 2026Ustekinumab Biosimilar (Uzpruvo) US FDA Approval Decision80% success
• Q4 2026Aflibercept Biosimilar Launch in US/EU70% success
• H1 2027Denosumab Biosimilar Phase 3 Data Readout60% success